Effect of The Receptor Activator of Nuclear Factor кB and RANK Ligand on In Vitro Differentiation of Cord Blood CD133(+) Hematopoietic Stem Cells to Osteoclasts

Overview

Journal Cell J

Specialty Cell Biology

Date 2016 Sep 8

PMID 27602313

Citations 2

Authors

Nasim Kalantari

Saeid Abroun

Masoud Soleimani

Saeid Kaviani

Mehdi Azad

Fatemeh Eskandari

Hossein Habibi

Affiliations

Soon will be listed here.

Abstract

Objective: Receptor activator of nuclear factor-kappa B ligand (RANKL) appears to be an osteoclast-activating factor, bearing an important role in the pathogenesis of multiple myeloma. Some studies demonstrated that U-266 myeloma cell line and primary myeloma cells expressed RANK and RANKL. It had been reported that the expression of myeloid and monocytoid markers was increased by co-culturing myeloma cells with hematopoietic stem cells (HSCs). This study also attempted to show the molecular mechanism of RANK and RANKL on differentiation capability of human cord blood HSC to osteoclast, as well as expression of calcitonin receptor (CTR) on cord blood HSC surface.

Materials And Methods: In this experimental study, CD133(+) hematopoietic stem cells were isolated from umbilical cord blood and cultured in the presence of macrophage colony-stimulating factor (M-CSF) and RANKL. Osteoclast differentiation was characterized by using tartrate-resistant acid phosphatase (TRAP) staining, giemsa staining, immunophenotyping, and reverse transcription-polymerase chain reaction (RT-PCR) assay for specific genes.

Results: Hematopoietic stem cells expressed RANK before and after differentiation into osteoclast. Compared to control group, flow cytometric results showed an increased expression of RANK after differentiation. Expression of CTR mRNA showed TRAP reaction was positive in some differentiated cells, including osteoclast cells.

Conclusion: Presence of RANKL and M-CSF in bone marrow could induce HSCs differentiation into osteoclast.

Citing Articles

Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes.

Vuoti E, Lehenkari P, Tuukkanen J, Glumoff V, Kylmaoja E Sci Rep. 2023; 13(1):3763.

PMID: 36882450 PMC: 9992388. DOI: 10.1038/s41598-023-30701-0.

Hira V, Breznik B, Vittori M, Loncq de Jong A, Mlakar J, Oostra R J Histochem Cytochem. 2019; 68(1):33-57.

PMID: 31566074 PMC: 6931169. DOI: 10.1369/0022155419878416.

References

Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J . Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003; 9(4):1436-40. View

Bezerra M, Carvalho J, Prokopowitsch A, Pereira R . RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res. 2005; 38(2):161-70. DOI: 10.1590/s0100-879x2005000200004. View

Edwards C, Zhuang J, Mundy G . The pathogenesis of the bone disease of multiple myeloma. Bone. 2008; 42(6):1007-13. PMC: 2474770. DOI: 10.1016/j.bone.2008.01.027. View

Blair J, Zheng Y, Dunstan C . RANK ligand. Int J Biochem Cell Biol. 2006; 39(6):1077-81. DOI: 10.1016/j.biocel.2006.11.008. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K . Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999; 190(12):1741-54. PMC: 2195707. DOI: 10.1084/jem.190.12.1741. View

Faust J, Lacey D, Hunt P, Burgess T, Scully S, Van G . Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem. 1999; 72(1):67-80. DOI: 10.1002/(sici)1097-4644(19990101)72:1<67::aid-jcb8>3.0.co;2-a. View

Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F . Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?. Oncologist. 2009; 14(3):264-75. DOI: 10.1634/theoncologist.2008-0087. View

Hodge J, Kirkland M, Aitken C, Waugh C, Myers D, Lopez C . Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone Miner Res. 2004; 19(2):190-9. DOI: 10.1359/JBMR.0301232. View

10.

Vega D, Maalouf N, Sakhaee K . CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007; 92(12):4514-21. DOI: 10.1210/jc.2007-0646. View

11.

Way K, Dinh H, Keene M, White K, Clanchy F, Lusby P . The generation and properties of human macrophage populations from hemopoietic stem cells. J Leukoc Biol. 2009; 85(5):766-78. DOI: 10.1189/jlb.1108689. View

12.

Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K . Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood. 2001; 98(8):2544-54. DOI: 10.1182/blood.v98.8.2544. View

13.

Kurihara N, Gluck S, Roodman G . Sequential expression of phenotype markers for osteoclasts during differentiation of precursors for multinucleated cells formed in long-term human marrow cultures. Endocrinology. 1990; 127(6):3215-21. DOI: 10.1210/endo-127-6-3215. View

14.

Feng X . RANKing intracellular signaling in osteoclasts. IUBMB Life. 2005; 57(6):389-95. DOI: 10.1080/15216540500137669. View

15.

Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S . Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001; 98(13):3527-33. DOI: 10.1182/blood.v98.13.3527. View

16.

Lari R, Kitchener P, Hamilton J . The proliferative human monocyte subpopulation contains osteoclast precursors. Arthritis Res Ther. 2009; 11(1):R23. PMC: 2688256. DOI: 10.1186/ar2616. View

17.

Nicholson G, Malakellis M, Collier F, Cameron P, Holloway W, Gough T . Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond). 2000; 99(2):133-40. View

18.

Miyamoto T, Arai F, Ohneda O, Takagi K, Anderson D, Suda T . An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. Blood. 2000; 96(13):4335-43. View

19.

Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S . Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007; 21(5):1079-88. PMC: 2346535. DOI: 10.1038/sj.leu.2404621. View

20.

Papadopoulou E, Batzios S, Dimitriadou M, Perifanis V, Garipidou V . Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia. 2010; 14(2):76-81. PMC: 2895290. View